PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Indeed, recent studies have reported that a systemic pan-AMPK activator improves glucose homeostasis in preclinical models [9] and that an AMPK activator targeting complexes containing AMPKβ1corrects non-alcoholic fatty liver disease (NAFLD) in primate preclinical models [10].